RNA therapeutics development

Developing the Next Generation of RNA Medicines Axelyf is advancing RNA medicines for oncology and autoimmune diseases — powered by AXL, a next-generation lipid nanoparticle platform validated for precise, potent delivery. Explore our Platform View Programs An Asset Development Company Built on Cutting Edge Delivery Science Axelyf is developing RNA therapeutics that address diseases where conventional approaches have fallen short. Our focus is on building and advancing proprietary drug candidates — starting with AX-004, our lead in vivo CAR-T program targeting solid tumors, and AX-003, targeting autoimmune hepatitis. Both programs are enabled by the AXL platform: a next-generation lipid nanoparticle delivery system validated in non-human primates and optimized with the help of ANNA™, our proprietary AI model for lipid design. Meet the Team Latest News

Read more

AI-driven lipid designdrug delivery sciencelipid chemistrylipid nanoparticle deliveryRNA biology

Bound Therapeutics is a preclinical-stage biotechnology company developing RNA-based therapies for rare and refractory diseases, with a primary focus on oncology. Its proprietary Magic Bullet Designer (MBD) platform uses AI and machine learning to design tissue-targeted peptide ligands for RNA drug delivery. The company was founded in 2015 and is located at the Cambridge Innovation Center in Philadelphia, PA.

Read more

AI-driven drug discoveryde novo peptide ligand designmachine learningnanoparticle engineeringpreclinical researchtissue-targeted drug delivery